Nebius Group NV vs Smith & Nephew plc — how do they compare? Nebius Group NV trades at $218.45 (market cap $46.37B), while Smith & Nephew plc trades at $30.45 (market cap $12.64B). The key difference: Nebius Group NV is far larger — about 3.7× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.57% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals.
| NBIS | SNN | |
|---|---|---|
Market Cap | $46.37B | $12.64B |
Sector | Technology | Health |
52-Week High | $286.69 | $38.70 |
52-Week Low | $50.40 | $28.73 |
Enterprise Value | $46.56B | $15.41B |
Dividend Yield | — | 2.57% |
Signals from Pluang's Aura AI — not financial advice
NBIS stock surged 22.06% to $216.92 on July 21, 2026, driven by NVIDIA's disclosure of a 9.3% stake, signaling strong AI cloud partnership potential. Despite a bearish technical signal, the company shows robust revenue growth projections, with 2026 net income margin expected at 93.08%. Recent earnings beat expectations in two of the last three quarters, though cash flow trends highlight significant investing outflows.
The outlook is bullish based on analyst consensus and strategic alliances, but risks include high valuation multiples and competitive pressures from tech giants. Investment opportunity centers on AI infrastructure demand, while caution is advised due to volatility and execution risks in scaling operations.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →